Evidence map›Paper›PMID 34796000›Full record

ArticleSovremennye tekhnologii v meditsine2021

COVID-19 in Patients with Diabetes: Clinical Course, Metabolic Status, Inflammation, and Coagulation Disorder.

D V Belikina, E S Malysheva, A V Petrov, T A Nekrasova, E S Nekaeva, A E Lavrova, D G Zarubina, K A Atduev, D M Magomedova, L G Strongin

Open access · diamondAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

D V BelikinaPhD Student, Department of Endocrinology and Internal Medicine; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
E S MalyshevaAssistant, Department of Endocrinology and Internal Medicine; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
A V PetrovAssociate Professor, Department of Endocrinology and Internal Medicine; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
T A NekrasovaProfessor, Department of Endocrinology and Internal Medicine; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
E S NekaevaHead of the Emergency Department; Infection Hospital for Patients with Novel Coronavirus Infection (COVID-19) at the Institute of Pediatrics of the University Hospital, Privolzhsky Research Medical University, 22, Bldg 1, Semashko St., Nizhny Novgorod, 603950, Russia.
A E LavrovaHead of the Department of Pediatrics; Infection Hospital for Patients with Novel Coronavirus Infection (COVID-19) at the Institute of Pediatrics of the University Hospital, Privolzhsky Research Medical University, 22, Bldg 1, Semashko St., Nizhny Novgorod, 603950, Russia.
D G ZarubinaStudent, Medical Faculty;Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
K A AtduevStudent, Medical Faculty;Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
D M MagomedovaStudent, Medical Faculty;Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
L G StronginProfessor, Head of the Department of Endocrinology and Internal Medicine Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
Privolzhsky Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Materials and Methods: The study included 64 patients with COVID-19; of them, 32 were with DM (main group) and 32 were DM-free (control group). The groups were formed according to the "case-control" principle. During hospitalization, the dynamics of clinical, glycemic, and coagulation parameters, markers of systemic inflammation, as well as kidney and liver functions were monitored and compared. Results: Among patients with DM, the course of viral pneumonia was more severe, as evidenced by a 2.2-fold higher number of people with extensive (>50%) lung damage (p=0.05), an increased risk of death according to the CURB-65 algorithm (1.3-fold, p=0.043), and a longer duration of insufficient blood oxygen saturation (p=0.0004). With the combination of COVID-19 and DM, hyperglycemia is persistent, without pronounced variability (MAGE - 1.5±0.6 mmol/L), the levels of C-reactive protein (p=0.028), creatinine (p=0.035), and fibrinogen (p=0.013) are higher, manifestations of hypercoagulability persist longer, including slower normalization of antithrombin III (p=0.012), fibrinogen (p=0.037), and D-dimer (p=0.035). Conclusion: The course of COVID-19 in patients with DM is associated with a high severity and extension of pneumonia, persistent decrease in oxygen supply, high hyperglycemia, accelerated renal dysfunction, systemic inflammation, and hypercoagulability.

Indexed as

Blood Coagulation DisordersCOVID-19Diabetes MellitusHumansInflammationSARS-CoV-2COVID-19diabetes mellitusglycemiahypercoagulationSARS-CoV-2systemic inflammation

Identifiers

PMID34796000
PMCPMC8596266
OpenAlexW3097111775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.